ArticleOncotarget2025

ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response.

Kyle R Cron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.